Skip to main content
Log in

Pharmacokinetics of mepindolol in patients with chronic renal failure

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Five patients with a creatinine clearance of 14 to 37 ml/min/1.73 m2 were each given an oral dose of 10 mg of the beta-blocker mepindolol sulphate (Corindolan). In addition, two dialysis patients received the same dose either during hemodialysis or on a dialysis-free day. Plasma levels of mepindolol were measured by a sensitive, specific HPLC method. Mepindolol was rapidly absorbed in all the patients. The maximum plasma level of 35±8 ng/ml was reached after 1.4±0.5 h. The half-life of disposition was 4.0±1.5 h. The area under the plasma concentration-time curve was 237±84 ng × h/ml. The data obtained were no different from those found in normal healthy volunteers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bolte H-D (1982) Betarezeptorenblocker, Pharmakokinetik und therapeutische Wirksamkeit. Internist 23: 616–623

    Google Scholar 

  2. Simon P, Meyrier A, Brissot P (1981) Uremia and the liver II. Drugs and the liver in the uremic patient. Nephron 29: 7–13

    Google Scholar 

  3. Aellig WH (1973) Isoprenaline antagonism and duration of action in exercise induced tachycardia of three β-adrenoceptor blocking drugs: pindolol, LF 17-895 and propranolol. Br J Pharmacol 47: 621 P

  4. Carrageta M (1982) Nicht-invasive Blutdrucküberwachung unter der Therapie mit Beta-Blockern. In: Hitzenberger G, Berzewski B (eds) Beta-Rezeptoren-Antagonisten in der Therapie der koronaren Herzkrankheit und der Hypertonie. Dustri-Verlag Karl Feistle, München-Deisenhofen, p 137–143

    Google Scholar 

  5. Raftery EB (1983) Klassifizierung der Beta-Blocker nach ihrer Wirkung auf Blutdruckschwankungen im tagesperiodischen Verlauf. In: Magometschnigg D, Hitzenberger G (eds) Blutdruckvariabilität. Uhlen Wien, p 109–117

    Google Scholar 

  6. Krause W, Kühne G, Täuber U (1980) Pharmacokinetics of mepindolol sulphate in animals. Eur J Drug Metab Pharmacokinet 5: 241–247

    Google Scholar 

  7. Hellenbrecht D, Lemmer B, Wiethold G, Grobecker H (1973) Measurement of hydrophobicity, surface activity, local anaesthesia and myocardial conduction velocity as quantitative parameters of the non-specific membrane activity of nine β-adrenergic blocking agents. Naunyn-Schmiedebergs Arch Pharmacol 277: 211–226

    Google Scholar 

  8. Bonelli J, Hitzenberger G, Krause W, Wendt H, Speck U (1980) Pharmacokinetics and pharmacodynamics of mepindolol sulphate. Int J Clin Pharmacol Ther Toxicol 18 [4]: 169–176

    Google Scholar 

  9. Krause W (1980) Determination of plasma mepindolol levels by high-performance liquid chromatography and electrochemical detection. J Chromatogr 181: 67–75

    Google Scholar 

  10. Krause W, Schwartzkopff W (1983) Plasma levels of mepindolol in healthy volunteers after oral doses of mepindolol sulphate. Arzneimittelforsch 33: 1306–1307

    Google Scholar 

  11. Ohnhaus EE, Nuesch E, Meier J, Kalberer F (1974) Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia. Eur J Clin Pharmacol 7: 25–29

    Google Scholar 

  12. Ohnhaus EE (1973) The pharmacokinetics of unchanged pindolol in patients with impaired renal function. Br J Pharmacol 47: 620–621

    Google Scholar 

  13. Oie S, Levy G (1975) Relationship between renal function and elemination kinetics of pindolol in man. Eur J Clin Pharmacol 9: 115–116

    Google Scholar 

  14. Ohnhaus EE, Heidemann H, Meier J, Maurer G (1982) Metabolism of pindolol in patients with renal failure. Eur J Clin Pharmacol 22 [5]: 423–428

    Google Scholar 

  15. Lavene D, Weiss YA, Safar ME, Loria Y, Agorus N, Georges D, Milliez PC (1977) Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function. J Clin Pharmacol 17: [8]: 501–508

    Google Scholar 

  16. Wood AJJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, Shand DG (1980) Propranolol, disposition in renal failure. Br J Clin Pharmacol 10: 561–566

    Google Scholar 

  17. Blair AD, Burgess ED, Maxwell BM, Cutler RE (1981) Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 29 [4]: 457–463

    Google Scholar 

  18. Berglund G, Descamps R, Thomis JA (1980) Pharmarcokinetics of sotalol after chronic administration to patients with renal insufficiency. Eur J Clin Pharmacol 18: 321–326

    Google Scholar 

  19. Kirch W, Köhler H, Mutschler E, Schäfer M (1981) Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 19: 65

    Google Scholar 

  20. McAinsh J, Holmes BF, Smith S, Hood D, Warren D (1980) Atenol kinetics in renal failure. Clin Pharmacol Ther 28 [3]: 302–309

    Google Scholar 

  21. Bianchetti G (1982) Betaxolol disposition in chronic renal insufficiency, hemodialysis and ambulatory peritoneal dialysis. Eur J Clin Invest 12 [2]: 2–5

    Google Scholar 

  22. Munn S, Bailey RR, Begg E, Ebert R (1980) Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment. NZ Med J 91: 289–291

    Google Scholar 

  23. Fabre J, Balant L, Rudhardt M, Blanchard P (1979) Particulations de la pharmacocinetique dans l'insuffisance renale: anomalie des metabolites et de la diffusion dans les tissus. Nouv Presse Méd 8: 2677–2682

    Google Scholar 

  24. Seiler KU, Schuster KJ, Meyer G-J, Niedermayer W, Wassermann O (1980) The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet 5: 192–198

    Google Scholar 

  25. Krause W (1982) The role of HPLC in pharmacokinetics. In: Molnar I (ed) Practical aspects of modern HPLC. de Gruyter, Berlin New York, p 197

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krause, W., Kampf, D. & Fischer, H.C. Pharmacokinetics of mepindolol in patients with chronic renal failure. Eur J Clin Pharmacol 27, 429–433 (1984). https://doi.org/10.1007/BF00549590

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00549590

Key words

Navigation